Opportunity radar
4,186,134 patents indexed · 165,974,948 citations · issued 2005-01-04 → 2026-05-05
Showing50 of 25,005
Pharma (A61K)Therapy methods (A61P)Med devices (A61M)Agriculture (A01)Hand tools (B25)Consumer (A47)Energy (H01M)AI / ML (G06N)
| Patent # | Title | Assets | Issued | Expires | Fwd cites | Score |
|---|---|---|---|---|---|---|
| 12521362 | Agent for treating, preventing, or improving psychiatric and nervous system disorders or symptoms | 🖼🧊📄§ | 2026-01-13 | 2040-09-25 | 0 | 31 |
| 12522631 | Compounds for use in the treatment of liver disease | 🖼🧊📄§ | 2026-01-13 | 2040-08-14 | 0 | 31 |
| 12521413 | Molecular basis of fatty liver inhibition by sodium borates | 🖼🧊📄§ | 2026-01-13 | 2040-11-25 | 0 | 31 |
| 12521361 | Use of sodium octanoate in preparation of medicine for improving the efficacy of cardiopulmonary resuscitation and post-resuscitation multiple organ dysfunction | 🖼🧊📄§ | 2026-01-13 | 2043-02-28 | 0 | 31 |
| 12521377 | Uses of (+)-B-dihydrotetrabenazine in methods of treating movement disorder | 🖼🧊📄§ | 2026-01-13 | 2038-03-29 | 0 | 31 |
| 12522663 | Multivalent binding molecules | 🖼🧊📄§ | 2026-01-13 | 2043-08-21 | 0 | 31 |
| 12521448 | Preparation of solid cyclodextrin complexes for ophthalmic active pharmaceutical ingredient delivery | 🖼🧊📄§ | 2026-01-13 | 2045-02-11 | 0 | 31 |
| 12521446 | Anti-CEACAM5 antibody drug conjugates | 🖼🧊📄§ | 2026-01-13 | 2045-02-26 | 0 | 31 |
| 12522651 | BCG car constructs and methods of their manufacture and use | 🖼🧊📄§ | 2026-01-13 | 2040-12-08 | 0 | 31 |
| 12521358 | Method for selecting cancer patients for whom combination therapy with retinoid and cancer therapeutic agent is effective, and combination medicament with retinoid and cancer therapeutic agent | 🖼🧊📄§ | 2026-01-13 | 2041-06-28 | 0 | 31 |
| 12522664 | Anti-CD20 antibody and uses thereof | 🖼🧊📄§ | 2026-01-13 | 2043-06-08 | 0 | 31 |
| 12521392 | Methods and compositions for promoting wound healing in a subject suffering from ectodermal dysplasias | 🖼🧊📄§ | 2026-01-13 | 2039-07-15 | 0 | 31 |
| 12522666 | CD22 targeting-moiety for the treatment of B-cell acute lymphoblastic leukemia (B-ALL) | 🖼🧊📄§ | 2026-01-13 | 2041-03-11 | 0 | 31 |
| 12521369 | Methods of improving renal function | 🖼🧊📄§ | 2026-01-13 | 2043-11-29 | 0 | 31 |
| 12522594 | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | 🖼🧊📄§ | 2026-01-13 | 2038-02-02 | 0 | 31 |
| 12522845 | Aav vectors encoding NF1 and uses thereof | 🖼🧊📄§ | 2026-01-13 | 2042-06-23 | 0 | 31 |
| 12521373 | Use of losartan for the treatment of fibrotic diseases, in particular epidermolysis bullosa | 🖼🧊📄§ | 2026-01-13 | 2040-12-14 | 0 | 31 |
| 12521344 | Non-aqueous gel composition | 🖼🧊📄§ | 2026-01-13 | 2043-02-01 | 0 | 31 |
| 12522635 | Amyloid peptide variants | 🖼🧊📄§ | 2026-01-13 | 2040-02-24 | 0 | 31 |
| 12521417 | Use of platelet-based products for treatment of capsular contracture proximate breast implant | 🖼🧊📄§ | 2026-01-13 | 2045-02-07 | 0 | 31 |
| 12521451 | CRISPR and AAV strategies for x-linked juvenile retinoschisis therapy | 🖼🧊📄§ | 2026-01-13 | 2040-11-07 | 0 | 31 |
| 12522844 | VSV chimeric vectors | 🖼🧊📄§ | 2026-01-13 | 2039-11-22 | 0 | 31 |
| 12522834 | DNA aptamers and use thereof | 🖼🧊📄§ | 2026-01-13 | 2039-07-19 | 0 | 31 |
| 12521443 | Conjugate production | 🖼🧊📄§ | 2026-01-13 | 2040-05-07 | 0 | 31 |
| 12522618 | Copper complexes for treatment of neurodegenerative disorders | 🖼🧊📄§ | 2026-01-13 | 2044-04-23 | 0 | 31 |
| 12521364 | Composition for preventing or treating neuropathic pain, containing syringaresinol | 🖼🧊📄§ | 2026-01-13 | 2040-09-25 | 0 | 31 |
| 12521351 | Delayed release oral pharmaceutical composition | 🖼🧊📄§ | 2026-01-13 | 2044-10-02 | 0 | 31 |
| 12522606 | Modified pyrrolo- and pyrazolo-pyrimidines for prostate cancer therapy | 🖼🧊📄§ | 2026-01-13 | 2041-01-07 | 0 | 31 |
| 12522572 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | 🖼🧊📄§ | 2026-01-13 | 2044-03-27 | 0 | 31 |
| 12522600 | Crystal form and salt form of bromine domain protein inhibitor and preparation method therefor | 🖼🧊📄§ | 2026-01-13 | 2041-01-19 | 0 | 31 |
| 12522636 | Compositions and methods for delivering CFTR polypeptides | 🖼🧊📄§ | 2026-01-13 | 2040-11-06 | 0 | 31 |
| 12522628 | Aryl glucoside derivative and use thereof in drug | 🖼🧊📄§ | 2026-01-13 | 2042-10-25 | 0 | 31 |
| 12521389 | Therapeutic approach to lung disease | 🖼🧊📄§ | 2026-01-13 | 2040-06-12 | 0 | 31 |
| 12521414 | Method for preventing or treating urological chronic pelvic pain syndrome | 🖼🧊📄§ | 2026-01-13 | 2042-06-08 | 0 | 31 |
| 12521394 | Therapeutic compositions and methods for treating cancers | 🖼🧊📄§ | 2026-01-13 | 2040-06-19 | 0 | 31 |
| 12521371 | Modulators of alpha-synuclein | 🖼🧊📄§ | 2026-01-13 | 2038-06-19 | 0 | 31 |
| 12521442 | ASH1L inhibitors and methods of treatment therewith | 🖼🧊📄§ | 2026-01-13 | 2043-12-05 | 0 | 31 |
| 12521416 | Anti-aging compositions and uses thereof | 🖼🧊📄§ | 2026-01-13 | 2042-01-05 | 0 | 31 |
| 12521350 | Liquid crystalline dosage form for administering a statin | 🖼🧊📄§ | 2026-01-13 | 2044-05-08 | 0 | 31 |
| 12522827 | Pan-genotypic agents against influenza virus and methods of using the same | 🖼🧊📄§ | 2026-01-13 | 2042-08-01 | 0 | 31 |
| 12521367 | Related formulations and methods related to eye irritation | 🖼🧊📄§ | 2026-01-13 | 2043-07-06 | 0 | 31 |
| 12523656 | Antibodies against SARS-CoV-2 spike protein | 🖼🧊📄§ | 2026-01-13 | 2042-03-23 | 0 | 31 |
| 12521415 | Accelerating repair of mucosal injury using gold(III) compounds | 🖼🧊📄§ | 2026-01-13 | 2041-07-29 | 0 | 31 |
| 12521412 | Nucleic acids and nucleic acid analogs for treating, preventing, and disrupting pathological polynucleotide-binding protein inclusions | 🖼🧊📄§ | 2026-01-13 | 2039-08-16 | 0 | 31 |
| 12522571 | Compounds, devices, and uses thereof | 🖼🧊📄§ | 2026-01-13 | 2043-12-05 | 0 | 31 |
| 12521359 | Composition for the treatment of muscle wasting | 🖼🧊📄§ | 2026-01-13 | 2040-06-29 | 0 | 31 |
| 12521356 | Compositions and methods for treating pain, inflammation, infection, malaria, and sepsis | 🖼🧊📄§ | 2026-01-13 | 2039-06-04 | 0 | 31 |
| 12521393 | Cytotoxicity targeting chimeras for CCR2-expressing cells | 🖼🧊📄§ | 2026-01-13 | 2044-02-09 | 0 | 31 |
| 12521378 | Administration of R-beta-hydroxybutyrate salt blend and related compounds in humans | 🖼🧊📄§ | 2026-01-13 | 2042-04-28 | 0 | 31 |
| 12521577 | Betacoronavirus RNA vaccines | 🖼🧊📄§ | 2026-01-13 | 2044-07-02 | 0 | 31 |